Tag : ACUTE PROMYELOCYTIC LEUKEMIA

Acute promyelocytic leukemia (APL) has historically been one of the most aggressive forms of leukemia and an oncological emergency, characterized by rapid progression and high early mortality rates.1 Traditional chemotherapy treatments often led to dismal prognoses, but the discovery of targeted therapies such as all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) has revolutionized its management.1 The ongoing evolution of ATO formulations is highlighted by an Acute Promyelocytic Leukaemia Asian Consortium (APL-AC) study, which examines the efficacy and safety of oral-ATO. This study underscores the potential of oral-ATO not only to enhance patient outcomes in APL but also to provide a more convenient and cost-effective option.2 In an interview with Omnihealth Practice, Dr. Gill Harinder Singh Harry, the study’s lead investigator, described how the development of an oral formulation of ATO has further transformed the treatment landscape, offering significant improvements in survival rates, quality of life (QoL), and healthcare resource utilization.